LEXINGTON, Mass., Nov. 7,
2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology
company focused on the development and commercialization of
innovative therapeutics for the treatment of cancer, today
announced upcoming presentations at the Society for Immunotherapy
of Cancer (SITC) 33rd Annual Meeting and participation
in an analyst-moderated Q&A panel at Cowen's 2nd
Annual IO NEXT Summit. Curis' poster presentations will take place
on Friday, Nov. 9, with a poster from
collaborator Aurigene on Saturday, Nov.
10, at Hall E of the Walter E. Washington Convention Center
in Washington, D.C. The Cowen
2nd Annual IO NEXT Summit will take place at the
Marriott Marquis in Washington,
D.C. featuring a discussion with Jim
Dentzer, President and CEO, and Dr. Robert Martell, Head of Research and
Development, in an analyst-hosted fireside chat.
In three posters at the SITC conference, Curis will present
evidence supporting the presence of high VISTA expression on tumor
cells, preclinical data supporting VISTA's ability to independently
suppress T cell responses, and Phase 1 clinical trial data of
CA-170 in patients with advanced tumors and lymphomas. In addition,
Curis collaborator Aurigene will present a poster detailing key
findings from its ongoing Phase 2 trial of CA-170 in patients with
advanced solid tumors and Hodgkin lymphoma who are immunotherapy
treatment-naïve.
Details of these presentations are as follows:
Cowen IO NEXT
Summit
|
|
|
Date/Time:
|
Friday, Nov. 09,
11:50 AM – 12:10 PM EST
|
Presenters:
|
Jim Dentzer,
President and Chief Executive Officer
Robert Martell, M.D.,
Ph.D., Head of Research and Development
|
Location:
|
Marriot Marquis
Washington, DC
|
Society for
Immunotherapy of Cancer 33rd Annual
Meeting
|
|
|
CA-170 Poster
Presentations from Curis:
|
|
|
Date/Time:
|
Friday, Nov. 9,
12:45 PM – 2:15 PM, 6:30 PM – 8:00 PM EST
|
Location:
|
Hall E, Walter E.
Washington Convention Center
|
|
|
Abstract
Number:
|
P135
|
|
|
Presentation
Title:
|
Integrative
genomic and proteomic analysis identifies cancer subtypes and
signaling networks associated with aberrant tumor expression of
VISTA
|
|
|
Abstract
Number:
|
P139
|
|
|
Presentation
Title:
|
Pharmacodynamic
effects of CA-170, a first-in-class small molecule oral immune
checkpoint inhibitor (ICI) dually targeting V-domain Ig suppressor
of T-cell activation (VISTA) and PDL1
|
|
|
Abstract
Number:
|
P341
|
|
|
Presentation
Title:
|
Phase 1 study of
CA-170, a first-in-class, orally available, small molecule immune
checkpoint inhibitor (ICI) dually targeting VISTA and PDL1, in
patients with advanced solid tumors or lymphomas
|
CA-170 Poster
Presentation from Aurigene:
|
|
|
Date/Time:
|
Saturday, Nov. 10,
12:20 PM – 1:50 PM, 7:00 PM – 8:30 PM EST
|
Location:
|
Hall E, Walter E.
Washington Convention Center
|
|
|
Abstract
Number:
|
P714
|
|
|
Presentation
Title:
|
Phase 2 trial of
CA-170, a novel oral small molecule dual inhibitor of immune
checkpoints VISTA and PD-1, in patients with advanced solid tumor
and Hodgkin lymphoma
|
About Curis, Inc.
Curis is a biotechnology company focused on the development and
commercialization of innovative therapeutics for the treatment of
cancer, including fimepinostat, which is being investigated in
clinical studies in patients with DLBCL and solid tumors. Curis is
also engaged in a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including, the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing
testing in a Phase 1 trial in patients with advanced solid tumors
and lymphomas, and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is
currently undergoing testing in a Phase 1 trial in patients with
non-Hodgkin lymphoma. Curis is also party to a collaboration with
Genentech, a member of the Roche Group, under which Genentech and
Roche are commercializing Erivedge® for the treatment of advanced
basal cell carcinoma. For more information, visit Curis's website
at www.curis.com.
View original
content:http://www.prnewswire.com/news-releases/curis-to-present-at-33rd-society-for-immunotherapy-of-cancer-annual-meeting-and-cowen-io-next-summit-300745977.html
SOURCE Curis, Inc.